PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Randomized Phase 2 ◽

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1093/annonc/mdx439 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2820-2826 ◽

Cited By ~ 28

Author(s):

P. Bossi ◽

R. Miceli ◽

L.D. Locati ◽

D. Ferrari ◽

S. Vecchio ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

SHR‐1316 , an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

Thoracic Cancer ◽

10.1111/1759-7714.13913 ◽

2021 ◽

Author(s):

Lan Mu ◽

Yan Song ◽

Kuaile Zhao ◽

Ying Liu ◽

Qingxia Fan ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Multicentre Phase ◽

Phase 2 Study ◽

Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01)

European Urology ◽

10.1016/j.eururo.2011.08.072 ◽

2011 ◽

Vol 60 (6) ◽

pp. 1251-1257 ◽

Cited By ~ 22

Author(s):

Stéphane Culine ◽

Aude Fléchon ◽

Aline Guillot ◽

Sylvestre Le Moulec ◽

Damien Pouessel ◽

...

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Transitional Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Tumor Group ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30755-5 ◽

2021 ◽

Vol 22 (4) ◽

pp. 463-475

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jérôme Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps6090 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS6090-TPS6090 ◽

Cited By ~ 5

Author(s):

Ezra E.W. Cohen ◽

Danny Rischin ◽

David G. Pfister ◽

Jan Baptist Vermorken ◽

Yufan Zhao ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05755-7 ◽

2020 ◽

Vol 183 (2) ◽

pp. 419-428 ◽

Cited By ~ 1

Author(s):

Richard S. Finn ◽

Katalin Boer ◽

Igor Bondarenko ◽

Ravindranath Patel ◽

Tamas Pinter ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽